
Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) – Investment analysts at Noble Financial decreased their FY2026 earnings per share (EPS) estimates for Cocrystal Pharma in a research note issued to investors on Tuesday, November 17th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings of ($0.83) per share for the year, down from their previous forecast of ($0.61). The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.76) per share. Noble Financial also issued estimates for Cocrystal Pharma’s Q4 2026 earnings at ($0.21) EPS and FY2027 earnings at ($0.70) EPS.
Several other brokerages also recently commented on COCP. HC Wainwright reaffirmed a “buy” rating on shares of Cocrystal Pharma in a research report on Friday, October 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cocrystal Pharma in a research note on Wednesday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.
Cocrystal Pharma Stock Performance
Shares of COCP stock opened at $0.95 on Thursday. Cocrystal Pharma has a 52-week low of $0.76 and a 52-week high of $2.03. The firm has a market capitalization of $18.30 million, a P/E ratio of -1.23 and a beta of 1.60. The stock has a 50 day moving average price of $1.06 and a 200 day moving average price of $1.10.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last released its earnings results on Monday, November 16th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.10 million.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.
Recommended Stories
- Five stocks we like better than Cocrystal Pharma
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
